Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3)

Journal of Crohn's and Colitis

Volumn 8, Issue 11, 2014, Pages 1529-1538

  Loras, C ^a,b   Gisbert, J P ^b,c   Saro, M C ^d   Piqueras, M ^e   Sanchez Montes C ^f   Barrio, J ^g   Ordas I ^b,h   Montserrat, A ⁱ   Ferreiro, R ^j   Zabana, Y ^a,b   Chaparro, M ^b,c   Fernandez Banares F ^a,b   Esteve, M ^a,b   Forné, Montserrat ^a   Rosinach, Mercè ^a   Espinós, Jorge Carlos ^a   Temiño, Rocio ^a   Gonzalo, Victoria ^a   Aceituno, Montserrat ^a   de la Coba Ortiz, Cristobal ^d   Barrio, Jesús ^g   Gil Simón, Paula ^g   Atienza, Ramón ^g   Guillermo Bastida, ^f   Boadas, Jaume ^e   Ortiz, Jordi ^e   Monfort, David ^e   Calvet, Xavier ^k   Villòria, Albert ^k   more..

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL DE CABUEÑES   (Spain)

^e Brain   (Spain)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ HOSPITAL DE SABADELL   (Spain)

^j University Hospital of Santiago de Compostela   (Spain)

^k Hospital Parc Taulí de Sabadell   (Spain)

more..

Author keywords

Anti TNF treatment; Hepatitis B; Hepatitis B vaccination; Hepatitis C; Inflammatory bowel disease

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; RECOMBINANT HEPATITIS B VACCINE; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA; VIRUS RNA;

ADULT; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SURVEILLANCE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVACCINATION; ULCERATIVE COLITIS; VACCINATION; AGE; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; GENETICS; HEPACIVIRUS; IMMUNIZATION; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; PHYSIOLOGY; TIME; VIRUS ACTIVATION; WATCHFUL WAITING; YOUNG ADULT;

ADULT; AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RNA, VIRAL; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VIRUS ACTIVATION; WATCHFUL WAITING; YOUNG ADULT;

EID: 84927786134     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.06.009     Document Type: Article

References (26)

1. Lok A.S., McMahon B.J. Chronic hepatitis B. Update 2009. Hepatology 2009, 50:661-662.
2. Lavanchy D. The global burden of hepatitis C. Liver Int 2009, 29:74-81.
3. Loras C., Saro C., Gonzalez-Huix F., Mínguez M., Merino O., Gisbert J.P., et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009, 104:57-63. GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa).
4. Chevaux J.B., Nani A., Oussalah A., Venard V., Bensenane M., Belle A., et al. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis 2010, 16:916-924.
5. Loras C., Gisbert J.P., Mínguez M., Merino O., Bujanda L., Saro C., REPENTINA study, GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa) Group, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010, 59:1340-1346.
6. Gisbert J.P., Menchén L., García-Sánchez V., Marín I., Villagrasa J.R., Chaparro M. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2012, 35:1379-1385.
7. Gisbert J.P., Villagrasa J.R., Rodríguez-Nogueiras A., Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012, 107:1460-1466.
8. Gisbert J.P., Chaparro M., Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011, 33:619-633.
9. Lok A.S., McMahon B.J., Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD) Chronic hepatitis B: update of recommendations. Hepatology 2004, 39:857-861.
10. Vida Pérez L., Gómez Camacho F., García Sánchez V., Iglesias Flores E.M., Castillo Molina L., Cerezo Ruiz A., et al. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med Clin (Barc) 2009, 132:331-335.
11. Altunöz M.E., Senateş E., Yeşil A., Calhan T., Ovünç A.O. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig Dis Sci 2012, 57:1039-1044.
12. Gisbert J.P., Villagrasa J.R., Rodríguez-Nogueiras A., Chaparro M. Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013, 19:554-558.
13. Werner J.M., Abdalla A., Gara N., Ghany M.G., Rehermann B. The hepatitis B vaccine protects re-exposed healthcare workers, but does not provide sterilizing immunity. Gastroenterology 2013, 145:1026-1034.
14. Banatvala J.E., Van Damme P. Hepatitis B vaccine - do we need boosters?. J Viral Hepat 2003, 10:1-6.
15. Poorolajal J., Mahmoodi M., Majdzadeh R., Nasseri-Moghaddam S., Haghdoost A., Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 2010, 8(28):623-631.
16. Stevens C.E., Alter H.J., Taylor P.E., Zang E.A., Harley E.J., Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 1984, 311:496-501.
17. Shouval D. Hepatitis B, vaccines. J Hepatol 2003, 39(Suppl. 1):S70-S76.
18. Hepatitis B vaccines: WHO position paper - recommendations. Vaccine 2010, 28:589-590.
19. Mereckiene J., Cotter S., Lopalco P., D'Ancona F., Levy-Bruhl D., Giambi C., et al. Hepatitis B immunisation programmes in European Union, Norway and Iceland: where we were in 2009?. Vaccine 2010, 28:4470-4477.
20. Viganò M., Degasperi E., Aghemo A., Lampertico P., Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther 2012, 12:193-207.
21. Papa A., Felice C., Marzo M., Andrisani G., Armuzzi A., Covino M., et al. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents. J Crohn's Colitis 2013, 7:113-119.
22. Katsanos K.H., Tsianos V.E., Zois C.D., Zioga H, Vagias I., Zervou E., Northwest Greece IBD Study Group, et al. Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature. J Crohn's Colitis 2010, 4:450-465.
23. Lee Y.H., Bae S.C., Song G.G. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2013, 31:118-121.
24. Lin M.V., Blonski W., Buchner A.M., Reddy K.R., Lichtenstein G.R. The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease. Dig Dis Sci 2013, 58:1149-1156.
25. Moses J., Alkhouri N., Shannon A., Raig K., Lopez R., Danziger-Isakov L., et al. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol 2012, 107:133-138.
26. Rahier J.F., Magro F., Abreu C., Armuzzi A., Ben-Horin S., Chowers Y., et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis 2014, 8:443-468.